Acceleron is a biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics.
Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone forming agent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neuromuscular diseases, and metabolic disorders. Acceleron Pharma, Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 5, 2006 | Debt Financing | $8M | 1 | Hercules Capital | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Apr 12, 2021
Tjommi
|
Pre-seed | €547K | FinTech | — |
Apr 11, 2021
Lendwill
|
Equity Crowdfunding | €376.79K | Affiliate Marketing | — |
Jul 1, 2020
Ready Player Me
|
Seed | $2.10M | 3D Technology | — |
Jan 1, 2014
Chain
|
Seed | $4.20M | Blockchain | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Hercules Capital | Yes | Debt Financing |